Skip to main content
PMC home page
Archives of Disease in Childhood. Fetal and Neonatal Edition logoLink to Archives of Disease in Childhood. Fetal and Neonatal Edition
. 2001 May;84(3):F172–F176. doi: 10.1136/fn.84.3.F172

A trial of recombinant human granulocyte colony stimulating factor for the treatment of very low birthweight infants with presumed sepsis and neutropenia

A Russell, A Emmerson, N Wilkinson, T Chant, D Sweet, H Halliday, B Holland, E Davies
PMCID: PMC1721238  PMID: 11320043

Abstract

OBJECTIVES—The primary objective was to investigate the safety of recombinant human granulocyte colony stimulating factor (rhG-CSF) for the treatment of very low birthweight infants (VLBW) with sepsis and relative neutropenia, specifically with regard to worsening of respiratory distress and thrombocytopenia and all cause mortality. Secondary objectives were to evaluate duration of ventilation, intensive care, and antibiotic use as markers of efficacy.
DESIGN—Neonates (⩽ 28 days) in intensive care, with birth weights of 500-1500 g, absolute neutrophil count (ANC) of ⩽ 5 × 109/l, and clinical evidence of sepsis, were randomly assigned to receive either rhG-CSF (10 µg/kg/day) administered intravenously (n = 13), or placebo (n = 15) for a maximum of 14 days, in addition to standard treatment and antibiotics. All adverse events, oxygenation index, incidence of thrombocytopenia, all cause mortality, duration of ventilation, intensive care and antibiotic treatment, and ANC recovery were compared between the two groups.
RESULTS—Adverse events and oxygenation index were not increased by, and thrombocytopenia was not attributable to, treatment with rhG-CSF. At 6 and 12 months postmenstrual age, there were significantly fewer deaths in the group receiving rhG-CSF (1/13 v 7/15; p ⩽ 0.038). There was a non-significant trend towards a reduction in duration of ventilation, intensive care, and antibiotic use in the rhG-CSF group. There was a significantly more rapid increase in ANC in the rhG-CSF treated babies (p < 0.001).
CONCLUSIONS—In a small randomised placebo controlled trial in a highly selected group of neonates, adjuvant treatment with rhG-CSF increased ANC rapidly, and no treatment related adverse events were identified. Mortality at 6 and 12 months postmenstrual age was significantly lower in the treatment group. A large trial investigating efficacy in a similar group of neonates is warranted.


Full Text

The Full Text of this article is available as a PDF (140.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnon S., Grigg J., Silverman M. Pulmonary inflammatory cells in ventilated preterm infants: effect of surfactant treatment. Arch Dis Child. 1993 Jul;69(1 Spec No):44–48. doi: 10.1136/adc.69.1_spec_no.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bedford Russell A. R., Davies E. G., Gibson F. M., Gordon-Smith E. C. The in vitro effects of granulocyte and granulocyte-macrophage colony-stimulating factor on interleukin-3-dependent proliferation of human neonatal circulating progenitor cells. Pediatr Res. 1995 May;37(5):630–633. doi: 10.1203/00006450-199505000-00013. [DOI] [PubMed] [Google Scholar]
  3. Boyle R. J., Chandler B. D., Stonestreet B. S., Oh W. Early identification of sepsis in infants with respiratory distress. Pediatrics. 1978 Nov;62(5):744–750. [PubMed] [Google Scholar]
  4. Bracho F., Goldman S., Cairo M. S. Potential use of granulocyte colon-stimulating factor and granulocyte-macrophage colony-stimulating factor in neonates. Curr Opin Hematol. 1998 May;5(3):215–220. doi: 10.1097/00062752-199805000-00012. [DOI] [PubMed] [Google Scholar]
  5. Christensen R. D., Rothstein G. Exhaustion of mature marrow neutrophils in neonates with sepsis. J Pediatr. 1980 Feb;96(2):316–318. doi: 10.1016/s0022-3476(80)80837-7. [DOI] [PubMed] [Google Scholar]
  6. Drossou-Agakidou V., Kanakoudi-Tsakalidou F., Sarafidis K., Taparkou A., Tzimouli V., Tsandali H., Kremenopoulos G. Administration of recombinant human granulocyte-colony stimulating factor to septic neonates induces neutrophilia and enhances the neutrophil respiratory burst and beta2 integrin expression. Results of a randomized controlled trial. Eur J Pediatr. 1998 Jul;157(7):583–588. doi: 10.1007/s004310050884. [DOI] [PubMed] [Google Scholar]
  7. Erdman S. H., Christensen R. D., Bradley P. P., Rothstein G. Supply and release of storage neutrophils. A developmental study. Biol Neonate. 1982;41(3-4):132–137. doi: 10.1159/000241541. [DOI] [PubMed] [Google Scholar]
  8. Gillan E. R., Christensen R. D., Suen Y., Ellis R., van de Ven C., Cairo M. S. A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia. Blood. 1994 Sep 1;84(5):1427–1433. [PubMed] [Google Scholar]
  9. Gregory J., Hey E. Blood neutrophil response to bacterial infection in the first month of life. Arch Dis Child. 1972 Oct;47(255):747–753. doi: 10.1136/adc.47.255.747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hutter J. J., Jr, Hathaway W. E., Wayne E. R. Hematologic abnormalities in severe neonatal necrotizing enterocolitis. J Pediatr. 1976 Jun;88(6):1026–1031. doi: 10.1016/s0022-3476(76)81069-4. [DOI] [PubMed] [Google Scholar]
  11. Kocherlakota P., La Gamma E. F. Preliminary report: rhG-CSF may reduce the incidence of neonatal sepsis in prolonged preeclampsia-associated neutropenia. Pediatrics. 1998 Nov;102(5):1107–1111. doi: 10.1542/peds.102.5.1107. [DOI] [PubMed] [Google Scholar]
  12. Levy S. B. Multidrug resistance--a sign of the times. N Engl J Med. 1998 May 7;338(19):1376–1378. doi: 10.1056/NEJM199805073381909. [DOI] [PubMed] [Google Scholar]
  13. Manroe B. L., Weinberg A. G., Rosenfeld C. R., Browne R. The neonatal blood count in health and disease. I. Reference values for neutrophilic cells. J Pediatr. 1979 Jul;95(1):89–98. doi: 10.1016/s0022-3476(79)80096-7. [DOI] [PubMed] [Google Scholar]
  14. Marshall D. D., Kotelchuck M., Young T. E., Bose C. L., Kruyer L., O'Shea T. M. Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association. Pediatrics. 1999 Dec;104(6):1345–1350. doi: 10.1542/peds.104.6.1345. [DOI] [PubMed] [Google Scholar]
  15. Mouzinho A., Rosenfeld C. R., Sánchez P. J., Risser R. Revised reference ranges for circulating neutrophils in very-low-birth-weight neonates. Pediatrics. 1994 Jul;94(1):76–82. [PubMed] [Google Scholar]
  16. Murch S. H., Costeloe K., Klein N. J., MacDonald T. T. Early production of macrophage inflammatory protein-1 alpha occurs in respiratory distress syndrome and is associated with poor outcome. Pediatr Res. 1996 Sep;40(3):490–497. doi: 10.1203/00006450-199609000-00020. [DOI] [PubMed] [Google Scholar]
  17. Ogden B. E., Murphy S. A., Saunders G. C., Pathak D., Johnson J. D. Neonatal lung neutrophils and elastase/proteinase inhibitor imbalance. Am Rev Respir Dis. 1984 Nov;130(5):817–821. doi: 10.1164/arrd.1984.130.5.817. [DOI] [PubMed] [Google Scholar]
  18. Perez E. M., Weisman L. E. Novel approaches to the prevention and therapy of neonatal bacterial sepsis. Clin Perinatol. 1997 Mar;24(1):213–229. [PubMed] [Google Scholar]
  19. Philip A. G. Detection of neonatal sepsis of late onset. JAMA. 1982 Jan 22;247(4):489–492. [PubMed] [Google Scholar]
  20. Rodwell R. L., Taylor K. M., Tudehope D. I., Gray P. H. Hematologic scoring system in early diagnosis of sepsis in neutropenic newborns. Pediatr Infect Dis J. 1993 May;12(5):372–376. doi: 10.1097/00006454-199305000-00004. [DOI] [PubMed] [Google Scholar]
  21. Russell A. R., Davies E. G., Ball S. E., Gordon-Smith E. Granulocyte colony stimulating factor treatment for neonatal neutropenia. Arch Dis Child Fetal Neonatal Ed. 1995 Jan;72(1):F53–F54. doi: 10.1136/fn.72.1.f53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Schelonka R. L., Yoder B. A., desJardins S. E., Hall R. B., Butler J. Peripheral leukocyte count and leukocyte indexes in healthy newborn term infants. J Pediatr. 1994 Oct;125(4):603–606. doi: 10.1016/s0022-3476(94)70018-4. [DOI] [PubMed] [Google Scholar]
  23. Schibler K. R., Osborne K. A., Leung L. Y., Le T. V., Baker S. I., Thompson D. D. A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis. Pediatrics. 1998 Jul;102(1 Pt 1):6–13. doi: 10.1542/peds.102.1.6. [DOI] [PubMed] [Google Scholar]
  24. Stoll B. J., Gordon T., Korones S. B., Shankaran S., Tyson J. E., Bauer C. R., Fanaroff A. A., Lemons J. A., Donovan E. F., Oh W. Early-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr. 1996 Jul;129(1):72–80. doi: 10.1016/s0022-3476(96)70192-0. [DOI] [PubMed] [Google Scholar]
  25. Stoll B. J., Gordon T., Korones S. B., Shankaran S., Tyson J. E., Bauer C. R., Fanaroff A. A., Lemons J. A., Donovan E. F., Oh W. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr. 1996 Jul;129(1):63–71. doi: 10.1016/s0022-3476(96)70191-9. [DOI] [PubMed] [Google Scholar]
  26. Sáez-Llorens X., McCracken G. H., Jr Sepsis syndrome and septic shock in pediatrics: current concepts of terminology, pathophysiology, and management. J Pediatr. 1993 Oct;123(4):497–508. doi: 10.1016/s0022-3476(05)80942-4. [DOI] [PubMed] [Google Scholar]
  27. Weiss M., Moldawer L. L., Schneider E. M. Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Blood. 1999 Jan 15;93(2):425–439. [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood. Fetal and Neonatal Edition are provided here courtesy of BMJ Publishing Group

RESOURCES